For the post-vaccination analysis, we studied 284,592 patients (age
52 ± 20 years; 57% female; 63% White, 10% Asian, 8.9% African Ameri-
can and 12% Hispanic ethnicity). The types of vaccinations received
included: 62% Pfizer-BioNTech (BNT162b2); 31% Moderna (mRNA-1273);
6.9% Johnson & Johnson/Janssen (Ad26.COV2.S); and <0.1% other vac-
cines, including AstraZeneca (ChAdOx1-S), Novavax (NVX-CoV2373)
and Sinovac (CoronaVac).
